At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 42 enrolled
Drug / intervention
LY3323795 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3323795 in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating LY3323795, Itraconazole, and 1 other intervention for Healthy. Completed, enrolled 42 participants across 1 site.
Detailed Summary
The main purpose of this study is to investigate the safety of LY3323795 and the effects it has on the body. The study drug or placebo (sugar pill) will be given by mouth to healthy participants. The study has three parts. Each participant may only enroll in one part. The study will last 14 to 43 days, depending on the part. Screening must be completed prior to study start.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartDec 2016
Primary CompletionJul 2017
TodayJul 2026
First PostedDec 12, 2016
Enrollment StartDec 12, 2016
Primary CompletionJul 21, 2017
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 9.6 years ago
Interventions
LY3323795drug
Administered orally
Itraconazoledrug
Administered orally
Placebodrug
Administered orally